EQL Pharma AB (publ)

OM:EQL Stock Report

Market Cap: SEK 738.2m

EQL Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:EQL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Mar 26SellSEK 1,234,586Axel SchorlingIndividual24,066SEK 51.30
23 Dec 25BuySEK 1,004,891Martin KristoffersonIndividual19,225SEK 52.27
12 Sep 25SellSEK 57,075Alexander BrisingIndividual667SEK 85.57

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EQL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,112,8963.86%
Institutions2,062,7177.16%
VC/PE Firms6,901,07024%
Private Companies8,717,14130.3%
General Public10,000,49934.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 14 shareholders own 66.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
29.5%
Cadila Pharmaceuticals Limited
8,717,141SEK 217.9m0%34.08%
23.4%
FÅRö Capital Ab
6,901,070SEK 172.5m0%95.18%
3.03%
Avanza Fonder AB
894,747SEK 22.4m0%0.02%
2.49%
Consensus Asset Management AB
735,287SEK 18.4m0%7.77%
2.24%
Sten Irwe
661,463SEK 16.5m0%no data
1.56%
Carnegie Fonder AB
460,662SEK 11.5m0%0.02%
1.32%
Axel Schorling
389,791SEK 9.7m0%no data
1.21%
Cliens Kapitalförvaltning AB
357,308SEK 8.9m0%0.05%
1.19%
Schroder Investment Management Limited
350,000SEK 8.7m0%no data
0.11%
Martin Kristofferson
31,512SEK 787.8k0%no data
0.034%
Anders Mansson
10,000SEK 250.0k0%no data
0.034%
Per Svangren
10,000SEK 250.0k0%no data
0.026%
Cornelia Lindström
7,630SEK 190.8k0%no data
0.0085%
Linda Neckmar
2,500SEK 62.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 14:48
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EQL Pharma AB (publ) is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdDNB Carnegie Commissioned Research